Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK of Tafenoquine Co-administered with ACTs
NCT02184637Phase 1Completed
- Sponsor
- GSK
- Start
- Jul 2014
- Primary completion
- Apr 2015
- Modality
- Classical Binding Small Molecules, Nucleic Acid-Directed Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of tafenoquine in malaria (5 arms), sponsored by GSK. Primary endpoints: Area Under the Concentration-time Curve at Day 56 and Maximum Observed Concentration at Day 56. Started Jul 2014; status: completed.
02
Drugs
tafenoquine
03
Conditions
malaria
Beyond the preview
Go deeper on NCT02184637.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02184637.